Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
3.35
Dollar change
+0.06
Percentage change
1.82
%
IndexRUT P/E- EPS (ttm)-1.97 Insider Own4.41% Shs Outstand61.13M Perf Week-2.90%
Market Cap194.10M Forward P/E- EPS next Y-1.99 Insider Trans0.00% Shs Float55.39M Perf Month9.48%
Income-121.30M PEG- EPS next Q-0.69 Inst Own43.89% Short Float24.50% Perf Quarter-26.37%
Sales0.00M P/S- EPS this Y-28.19% Inst Trans-13.89% Short Ratio36.33 Perf Half Y86.11%
Book/sh-1.23 P/B- EPS next Y17.63% ROA-35.90% Short Interest13.57M Perf Year-45.97%
Cash/sh3.98 P/C0.84 EPS next 5Y- ROE-576.33% 52W Range0.92 - 7.80 Perf YTD2.45%
Dividend Est.- P/FCF- EPS past 5Y6.37% ROI-32.23% 52W High-57.04% Beta1.35
Dividend TTM- Quick Ratio4.76 Sales past 5Y34.87% Gross Margin- 52W Low264.13% ATR (14)0.27
Dividend Ex-Date- Current Ratio4.76 EPS Y/Y TTM-364.76% Oper. Margin0.00% RSI (14)46.51 Volatility4.96% 6.89%
Employees198 Debt/Eq- Sales Y/Y TTM-100.00% Profit Margin- Recom2.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-17.90% Payout- Rel Volume0.30 Prev Close3.29
Sales Surprise- EPS Surprise-12.32% Sales Q/Q- EarningsMay 15 AMC Avg Volume373.52K Price3.35
SMA20-4.88% SMA50-2.79% SMA2007.19% Trades Volume110,574 Change1.82%
Date Action Analyst Rating Change Price Target Change
Dec-08-22Downgrade UBS Buy → Neutral $12 → $2
Nov-08-22Downgrade BofA Securities Neutral → Underperform $8 → $3
Jun-08-22Downgrade BofA Securities Buy → Neutral $12 → $4
Oct-08-21Downgrade JP Morgan Neutral → Underweight
Oct-01-21Downgrade Wedbush Neutral → Underperform
Oct-01-21Downgrade Maxim Group Buy → Hold
Sep-27-21Initiated JP Morgan Neutral $15
Feb-01-21Initiated UBS Buy $25
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
May-16-24 01:10PM
03:10AM
May-15-24 08:55PM
04:11PM
04:02PM
08:50AM Loading…
May-10-24 08:50AM
May-09-24 08:50AM
Apr-02-24 12:41PM
11:22AM
Apr-01-24 09:53PM
05:32PM
04:17PM
04:02PM
Mar-27-24 08:30AM
Mar-17-24 10:02AM
09:00AM Loading…
Feb-20-24 09:00AM
Feb-07-24 09:34AM
Feb-01-24 09:11AM
Dec-24-23 01:08PM
Nov-11-23 03:01PM
Nov-10-23 09:43AM
Nov-09-23 04:33PM
04:02PM
Nov-06-23 08:00AM
Nov-03-23 09:05AM
Nov-02-23 09:05AM
Oct-19-23 08:30AM
Oct-16-23 08:36AM
07:59AM
07:44AM
07:30AM Loading…
07:30AM
Aug-09-23 08:08AM
08:00AM
Aug-04-23 08:00AM
Jun-21-23 08:30AM
Jun-12-23 02:47PM
08:45AM
Jun-01-23 11:00AM
May-09-23 04:41PM
04:02PM
May-04-23 04:06PM
Apr-25-23 09:25AM
Apr-10-23 08:45AM
Mar-29-23 09:07AM
Mar-28-23 09:34AM
Mar-14-23 11:11AM
10:06AM
Mar-13-23 04:02PM
Mar-10-23 03:37PM
Mar-07-23 09:00AM
Feb-09-23 02:43PM
Feb-06-23 11:30AM
08:50AM
Nov-09-22 04:02PM
Nov-08-22 08:30AM
Nov-04-22 09:00AM
Nov-03-22 09:00AM
Oct-03-22 07:10AM
Sep-15-22 10:51AM
09:06AM
09:02AM
Aug-17-22 08:40AM
Aug-10-22 05:01PM
Aug-09-22 04:02PM
Aug-08-22 11:35AM
Aug-04-22 09:55AM
08:30AM
Jul-29-22 02:48PM
08:45AM
Jul-05-22 05:46PM
Jun-15-22 08:00AM
May-10-22 04:02PM
May-04-22 08:30AM
Apr-20-22 08:45AM
Mar-01-22 04:02PM
08:59AM
Feb-28-22 08:34AM
Feb-24-22 07:00AM
Feb-03-22 09:38AM
Jan-20-22 06:54AM
Jan-19-22 05:52PM
Dec-30-21 05:11PM
Dec-23-21 09:10AM
Dec-20-21 09:30AM
Dec-15-21 11:34AM
Dec-03-21 08:17PM
Dec-02-21 08:22PM
07:30AM
05:58AM
Nov-30-21 07:42AM
Nov-09-21 06:25PM
04:02PM
Nov-05-21 04:45PM
08:40AM
08:30AM
Nov-04-21 10:53AM
08:30AM
Nov-01-21 04:35PM
03:01PM
Oct-31-21 06:19AM
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Demopulos Gregory A MDChairman, CEO & PresidentNov 17 '23Buy1.6815,00025,200123,945Nov 21 08:11 PM
Demopulos Peter A MDDirectorNov 15 '23Buy1.5310,00015,300208,516Nov 17 09:46 PM